IRMD IRADIMED CORP
FY2025 10-K
IRADIMED CORP (IRMD) filed its fiscal year 2025 10-K annual report with the SEC on Mar 6, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Development and sale of MRI compatible medical devices, notably IV infusion pumps and patient vital signs monitors for safe MRI environment use
- • New product emphasis: MRidium 3870 MRI Compatible IV Infusion Pump System launched in 2025 with Remote Display Unit for control from MRI control room
Management Discussion & Analysis
- • Revenue $83.8M in 2025, up 14.4% YoY from $73.2M in 2024, driven by U.S. sales +$10.0M (16.4%) and international sales +$0.6M (4.8%)
- • Operating margin 31.2% in 2025 vs 30.0% in 2024; gross profit margin stable at 77% both years
Risk Factors
- • FDA regulatory risk: potential refusal or revocation of 510(k) clearances affecting MRidium infusion pumps and 3880 patient monitors
- • Geopolitical risk: supply chain disruption from tariffs, trade restrictions, and political instability impacting sourcing of proprietary raw materials
Get deeper insights on IRADIMED CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.